Geron Operating Income Over Time
| GERN Stock | USD 1.65 0.07 4.07% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Geron Performance and Geron Correlation. Will Biotechnology sector continue expanding? Could Geron diversify its offerings? Factors like these will boost the valuation of Geron. Market participants price Geron higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Geron data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.671 | Return On Assets | Return On Equity |
Understanding Geron requires distinguishing between market price and book value, where the latter reflects Geron's accounting equity. The concept of intrinsic value - what Geron's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Geron's price substantially above or below its fundamental value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Geron's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Geron and related stocks such as Day One Biopharmaceu, Rezolute, and Arvinas Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (13.8 M) | (72.7 M) | (146.9 M) | (206.1 M) | (217.3 M) | (127.8 M) | (134.1 M) |
| RZLT | (45.7 K) | (45.7 K) | (6.1 M) | (5.2 M) | (10.7 M) | (15 M) | (20.3 M) | (28.7 M) | (25.9 M) | (20.5 M) | (22.9 M) | (41.8 M) | (56 M) | (70.4 M) | (79.9 M) | (71.9 M) | (68.3 M) |
| ARVN | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (16.5 M) | (24.8 M) | (43.8 M) | (51.5 M) | (124.9 M) | (195.3 M) | (263.2 M) | (401.5 M) | (250.2 M) | (118.5 M) | (124.4 M) |
| VALN | (1.4 M) | (4.5 M) | (12.8 M) | (20.9 M) | (23.8 M) | (19.9 M) | (42.6 M) | (4 M) | 6.3 M | (811 K) | (55.1 M) | (61.4 M) | (113.4 M) | (82.1 M) | 13.3 M | 12 M | 12.6 M |
| TYRA | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (9.3 M) | (26.3 M) | (58.9 M) | (79.9 M) | (104.2 M) | (93.8 M) | (89.1 M) |
| VIR | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (118.7 M) | (178 M) | (297 M) | 420.8 M | 833.1 M | (684.3 M) | (587.2 M) | (468 M) | (444.6 M) |
| SVRA | (3.7 M) | (13.4 M) | (15.6 M) | (21.5 M) | (29.3 M) | (39.4 M) | (10.9 M) | (30 M) | (70 M) | (79 M) | (49.3 M) | (41.5 M) | (38.8 M) | (60 M) | (103.2 M) | (92.9 M) | (88.2 M) |
| REPL | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (19.2 M) | (30.9 M) | (56.2 M) | (82.8 M) | (121.5 M) | (177.1 M) | (234.8 M) | (261.6 M) | (235.5 M) | (223.7 M) |
| LENZ | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (13.5 M) | (60.4 M) | (10.5 M) | (72.4 M) | (58.6 M) | (52.7 M) | (55.4 M) |
| AVBP | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (36.9 M) | (74.6 M) | (94.3 M) | (94.3 M) | (84.9 M) | (89.1 M) |
Geron and related stocks such as Day One Biopharmaceu, Rezolute, and Arvinas Operating Income description
Operating Income is the amount of profit realized from Geron operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Geron is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Geron | GERN |
| Classification | Cancer Fighters |
| Business Address | 919 East Hillsdale |
| Exchange | NASDAQ Exchange |
USD 1.65
Check out Geron Performance and Geron Correlation. To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Geron technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.